Neumora Therapeutics (NMRA) Non Operating Income (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Non Operating Income of -$564000.0 for Q1 2026, down 118.5% year-over-year from $3.0 million in Q1 2025, and up 41.86% quarter-over-quarter from -$970000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Non Operating Income (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Non Operating Income history runs 5 years deep, the most recent figure standing at -$564000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 118.5% year-over-year to -$564000.0; the TTM figure through Mar 2026 stood at $745000.0 (down 95.5% YoY), while the FY2025 annual figure was $4.4 million, down 78.05% from the prior year.
- Non Operating Income for Q1 2026 stood at -$564000.0, up from -$970000.0 in the prior quarter.
- The five-year high for Non Operating Income was $6.4 million in Q1 2024, with the low at -$970000.0 in Q4 2025.
- The 5-year median for Non Operating Income is $3.6 million (2023), against an average of $2.9 million.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income jumped 205.01% in 2023, then slumped 123.64% in 2025.
- Neumora Therapeutics' Non Operating Income stood at $2.2 million in 2022, then surged by 155.75% to $5.5 million in 2023, then slipped by 25.97% to $4.1 million in 2024, then plunged by 123.64% to -$970000.0 in 2025, then surged by 41.86% to -$564000.0 in 2026.
- Business Quant data shows NMRA's Non Operating Income at -$564000.0 in Q1 2026, -$970000.0 in Q4 2025, and $945000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -564,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -564,000.00 |
| Dec 31, 2025 | -970,000.00 |
| Sep 30, 2025 | 945,000.00 |
| Jun 30, 2025 | 1.33 Mn |
| Mar 31, 2025 | 3.05 Mn |
| Dec 31, 2024 | 4.10 Mn |
| Sep 30, 2024 | 4.15 Mn |
| Jun 30, 2024 | 5.25 Mn |
| Mar 31, 2024 | 6.35 Mn |
| Dec 31, 2023 | 5.54 Mn |
| Sep 30, 2023 | 3.84 Mn |
| Jun 30, 2023 | 3.56 Mn |
| Mar 31, 2023 | 3.57 Mn |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | 1.26 Mn |